Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information (Tables)

v3.26.1
Segment Information (Tables)
12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Profit and Loss From Segments For additional information on the year over year change of segment expenses refer to Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

 

 

Year Ended December 31,

 

 

 

2025

 

 

2024

 

 

 

(in thousands)

 

Research and development expenses:

 

 

 

 

 

 

Personnel

 

$

46,934

 

 

$

39,239

 

Clinical trials

 

 

39,581

 

 

 

22,286

 

Manufacturing of preclinical and clinical supplies

 

 

38,240

 

 

 

15,523

 

Development services

 

 

15,350

 

 

 

16,417

 

License of intellectual property

 

 

 

 

 

1,523

 

Other research and development costs (1)

 

 

2,569

 

 

 

2,215

 

General and administration expenses

 

 

29,567

 

 

 

27,938

 

Interest income

 

 

(6,031

)

 

 

(10,025

)

Interest expense

 

 

2,004

 

 

 

748

 

Other income, net

 

 

(358

)

 

 

 

Net loss

 

$

167,856

 

 

$

115,864

 

 

(1) Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.